Evidence map›Paper›PMID 42862171›Full record

ArticleeLife2026

Large-scale prospective evaluation of co-folding across hundreds of Mac1-ligand complexes and three virtual screens.

Jongbin Kim, Galen J Correy, Brendan W Hall, Moira M Rachman, Olivier Mailhot, Takaya Togo, Ryan L Gonciarz, Priyadarshini Jaishankar, R Jeffrey Neitz, Eric R Hantz and 10 more

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Target discovery and drug design in the era of artificial intelligence.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Jongbin Kim *Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0009-0007-3405-7880
Galen J Correy *Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0001-5155-7325
Brendan W Hall *Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.
Moira M RachmanDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.
Olivier MailhotDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-7533-4561
Takaya TogoDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0003-0243-0760
Ryan L GonciarzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-6600-7032
Priyadarshini JaishankarDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0009-0005-2013-8941
R Jeffrey NeitzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-2247-9345
Eric R HantzDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-2588-7619
Yagmur U DorukHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States.
Maisie G V StevensHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0009-0004-9732-0349
Morgan E DiolaitiHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0001-5900-3060
Rashad ReidDepartment of Biological and Medical Informatics, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0009-0001-1513-8614
Saumya GopalkrishnanQuantitative Biosciences Institute (QBI), University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0009-0003-6713-4492
Nevan J KroganDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.
Adam R RensloDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States.
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-6098-7367
James S FraserDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-5080-2859

Funding

Targeting Viroporins and Coronavirus M ProteinU19AI171110 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$103.4M
A Synchrotron Radiation Structural Biology ResourcesP30GM133894 · NIGMS · STANFORD UNIVERSITY · PI Ritimukta Sarangi · 2020 to 2026
$43.3M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6M
Development and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5M
Equipment for Discovering and Manipulating Macromolecular Conformational EnsemblesR35GM145238 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Solomon Fraser · 2022 to 2026
$3.1M
NIAID NIH HHS U19 AI171110NIGMS NIH HHS P30 GM124169NIGMS NIH HHS P30 GM133894NIGMS NIH HHS R35 GM122481NIGMS NIH HHS R35 GM145238NIH HHS GM122481NIH HHS GM145238NIH HHS U19AI171110
6 · The paper itself

Abstract

Accurate prediction of ligand-bound protein complexes and ranking them by affinity are central problems in drug discovery. While deep-learning co-folding methods can help address these challenges, their evaluation has been hampered by the difficulties in assessing independence from training data and insufficiently large test sets. Here, we test the ability of co-folding methods to predict the structures of 551 ligands, 489 of which are of sufficient quality for evaluation, bound to the SARS-CoV-2 NSP3 macrodomain (Mac1) that were determined after the training cutoff dates. AlphaFold3 (AF3), Boltz-2, and Chai-1 each reproduced >50% of the Mac1 ligand poses to better than 2 Å root-mean-square deviation of experiment. Despite the potential for co-folding to describe protein conformational changes that stabilize ligand binding, we did not find that common conformational rearrangements, including peptide flip and a large loop opening, were recapitulated by the co-folding prediction. For AF3 and Chai-1, ligand pose prediction confidence weakly, but significantly, tracked experimental potency, while DOCK3.7 energies were only weakly correlated. Boltz-2 affinity predictions showed the strongest correlation with measured potency and, after calibration, achieved lower mean absolute error than a baseline predictor. We next assessed whether co-folding scores could rescore docking hit lists to distinguish true ligands from non-binders among hundreds of molecules prospectively experimentally tested against AmpC β-lactamase, the dopamine D4, and the σ

Indexed as

Protein FoldingViral Nonstructural ProteinsDrug DiscoveryHumansLigandsProtein BindingProtein ConformationSARS-CoV-2LigandsORF1ab polyprotein, SARS-CoV-2Viral Nonstructural Proteinsco-foldingdockingdrug designE. colimachine learningmolecular biophysicsstructural biologystructure predictionX-ray crystallography

Identifiers

PMID42862171
PMCPMC13657626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.